Literature DB >> 16364302

P70 S6 kinase mediates tau phosphorylation and synthesis.

Jin-Jing Pei1, Wen-Lin An, Xin-Wen Zhou, Takeshi Nishimura, Jan Norberg, Eirikur Benedikz, Jürgen Götz, Bengt Winblad.   

Abstract

Currently, we found that the 70-kDa p70 S6 kinase (p70S6K) directly phosphorylates tau at S262, S214, and T212 sites in vitro. By immunoprecipitation, p-p70S6K (T421/S424) showed a close association with p-tau (S262 and S396/404). Zinc-induced p70S6K activation could only upregulate translation of total S6 and tau but not global proteins in SH-SY5Y cells. The requirement of p70S6K activation was confirmed in the SH-SY5Y cells that overexpress wild-type htau40. Level of p-p70S6K (T421/S424) was only significantly correlated with p-tau at S262, S214, and T212, but not T212/S214, in Alzheimer's disease (AD) brains. These suggested that p70S6K might contribute to tau related pathologies in AD brains.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16364302     DOI: 10.1016/j.febslet.2005.11.059

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  43 in total

Review 1.  Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease.

Authors:  Yanina Ivashko Pachima; Liu-yao Zhou; Peng Lei; Illana Gozes
Journal:  J Mol Neurosci       Date:  2016-02       Impact factor: 3.444

2.  mTOR-mediated hyperphosphorylation of tau in the hippocampus is involved in cognitive deficits in streptozotocin-induced diabetic mice.

Authors:  Shan Wang; Shan-lei Zhou; Fang-yuan Min; Jin-ju Ma; Xia-jie Shi; Erika Bereczki; Jing Wu
Journal:  Metab Brain Dis       Date:  2014-03-30       Impact factor: 3.584

3.  Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ.

Authors:  Arne Ittner; Lars M Ittner; Prita Riana Asih; Amanda R P Tan; Emmanuel Prikas; Josefine Bertz; Kristie Stefanoska; Yijun Lin; Alexander M Volkerling; Yazi D Ke; Fabien Delerue
Journal:  Acta Neuropathol       Date:  2020-07-29       Impact factor: 17.088

Review 4.  Tau in Alzheimer disease and related tauopathies.

Authors:  K Iqbal; F Liu; C-X Gong; I Grundke-Iqbal
Journal:  Curr Alzheimer Res       Date:  2010-12       Impact factor: 3.498

5.  Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation.

Authors:  Siddhartha Mondragón-Rodríguez; Emilie Trillaud-Doppia; Anthony Dudilot; Catherine Bourgeois; Michel Lauzon; Nicole Leclerc; Jannic Boehm
Journal:  J Biol Chem       Date:  2012-07-25       Impact factor: 5.157

6.  Pazopanib Reduces Phosphorylated Tau Levels and Alters Astrocytes in a Mouse Model of Tauopathy.

Authors:  Monica Javidnia; Michaeline L Hebron; Yue Xin; Nikolas G Kinney; Charbel E-H Moussa
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

7.  Tau phosphorylation at Alzheimer's disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated.

Authors:  Kanae Ando; Mikiko Oka; Yosuke Ohtake; Motoki Hayashishita; Sawako Shimizu; Shin-Ichi Hisanaga; Koichi M Iijima
Journal:  Biochem Biophys Res Commun       Date:  2016-08-09       Impact factor: 3.575

8.  Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.

Authors:  Zhi Tang; Erika Bereczki; Haiyan Zhang; Shan Wang; Chunxia Li; Xinying Ji; Rui M Branca; Janne Lehtiö; Zhizhong Guan; Peter Filipcik; Shaohua Xu; Bengt Winblad; Jin-Jing Pei
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

Review 9.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

10.  Confronting complexity in late-onset Alzheimer disease: application of two-stage analysis approach addressing heterogeneity and epistasis.

Authors:  Tricia A Thornton-Wells; Jason H Moore; Eden R Martin; Margaret A Pericak-Vance; Jonathan L Haines
Journal:  Genet Epidemiol       Date:  2008-04       Impact factor: 2.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.